Genomic Experimental Approaches in Oncology -- Toward the Realization of the Promise of Microarrays in Oncology -- Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response -- Proteomic Analysis in Cancer Patients -- MicroRNAs and Discovery of New Targets -- Pharmacogenomics of the National Cancer Institute's 60-Tumor Cell Panel -- Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers -- Pharmacogenomics of Toxicity and Response of Chemotherapy -- Concordance Between Tumor and Germline DNA -- Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer -- BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients -- Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients -- Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene -- Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies -- DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer -- Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer -- Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment -- Microarray Profiling in Breast Cancer Patients -- Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response -- Pharmacogenomics in Clinical Drug Development in Oncology -- Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective -- Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development -- Toxicogenomics Application to Oncology Drug Development -- Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches. The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.